AM-7438

In today's world, AM-7438 has become a topic of great relevance and interest to a wide spectrum of society. Whether on a personal, professional or academic level, AM-7438 has captured the attention of millions of people around the world. It is a phenomenon that has generated debate, reflection and analysis in multiple disciplines, raising both enthusiasm and concern. In order to shed light on AM-7438 and its impact on our daily lives, in this article we will explore its different facets, investigate its origin and evolution, and analyze the possible implications it has for the future.

AM-7438
Identifiers
  • 3-cyanopropyl 2-chromen-3-yl]-2-methylpropanoate
CAS Number
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H31NO4
Molar mass397.515 g·mol−1
3D model (JSmol)
  • CC1=CC2(C1)C3=C(C=C(C=C3OC2(C)C)C(C)(C)C(=O)OCCCC#N)O
  • InChI=1S/C24H31NO4/c1-15-8-9-18-17(12-15)21-19(26)13-16(14-20(21)29-24(18,4)5)23(2,3)22(27)28-11-7-6-10-25/h8,13-14,17-18,26H,6-7,9,11-12H2,1-5H3/t17-,18-/m1/s1
  • Key:PGSJGFYQNYPKOJ-QZTJIDSGSA-N

AM-7438 is a drug which is a cannabinoid receptor agonist, developed by the research team led by Dr Alexandros Makriyannis. It is a derivative of Δ8-THC which has been substituted with a side chain containing a metabolically labile ester group, allowing the molecule to be rapidly metabolised to an inactive form, in a similar manner to drugs such as remifentanil, remimazolam and SN 35210. This means that while AM-7438 retains potent cannabinoid effects, it has a much shorter duration of action than most related compounds.[1]


References

  1. ^ Nikas SP, Sharma R, Paronis CA, Kulkarni S, Thakur GA, Hurst D, Wood JT, Gifford RS, Rajarshi G, Liu Y, Raghav JG, Guo JJ, Järbe TU, Reggio PH, Bergman J, Makriyannis A (January 2015). "Probing the carboxyester side chain in controlled deactivation (−)-δ(8)-tetrahydrocannabinols". Journal of Medicinal Chemistry. 58 (2): 665–81. doi:10.1021/jm501165d. PMC 4306527. PMID 25470070.